Eli Lilly and Company v Generic Health Pty Ltd

Eli Lilly and Company initiated proceedings against Generic Health Pty Ltd in the Federal Court of Australia, contending that the respondent had infringed or threatened to infringe claims 1, 8 and 9 of certain patents. The dispute centred around the interpretation and validity of these claims, particularly in relation to the particle size of a drug known as raloxifene contained in Generic Health's product. The applicants sought to establish a prima facie case for final relief against the respondent's alleged infringement of their intellectual property rights. The central legal issues for the court to resolve included the proper construction of the patent claims, whether the respondent's product met the specifications outlined in those claims, and whether there was a likelihood of infringement if the respondent proceeded with their planned activities.

The court considered the scientific evidence provided by the parties' experts, notably Dr Luk, Professor Polli, and Professor Buckton. Dr Luk's affidavits were crucial in assessing the particle size measurements of the raloxifene in the samples provided by Generic Health. The court needed to determine the reliability and relevance of Dr Luk's test results and protocols, as well as the objections raised by the respondent regarding the admissibility of certain affidavits. The court also examined the opinions of Professor Polli and Professor Buckton, which provided differing views on the interpretation and significance of the particle size data.

In its reasoning, the court found that the applicants had demonstrated a prima facie case for final relief. The evidence presented by Dr Luk was deemed reliable and relevant, supporting the applicants' claims regarding the particle size specifications of the raloxifene. The court accepted that the respondent's product did not meet the critical particle size criteria outlined in the patents, thereby establishing a likelihood of infringement. The court ruled in favour of the applicants, granting the sought relief against the respondent's alleged infringement.

The final orders included an injunction preventing Generic Health from manufacturing, using, or selling the product that infringed the patents, as well as an order for the delivery up of any infringing products. The court also ordered that the matter be listed for further directions to address the remaining issues in the proceeding.